These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3991970)

  • 1. [Anti-collagen IV antibodies in patients with scleroderma and idiopathic Raynaud's phenomenon].
    Gabrielli A; Montroni M; Rupoli S; Caniglia ML; Danieli G
    Recenti Prog Med; 1985 Jan; 76(1):21-2. PubMed ID: 3991970
    [No Abstract]   [Full Text] [Related]  

  • 2. [Raynaud's phenomenon and anti-centromeric antibodies].
    Marquet R; Villar MM; Ordi J; de la Figuera M; Vilardell M
    Med Clin (Barc); 1984 Jun; 83(3):129-30. PubMed ID: 6482556
    [No Abstract]   [Full Text] [Related]  

  • 3. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticentromere antibody and Raynaud's phenomenon.
    Czirják L; Schlammadinger J; Szegedi G
    Dermatologica; 1991; 183(1):55. PubMed ID: 1769420
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibodies to high mobility group proteins in systemic sclerosis.
    Ayer LM; Sénecal JL; Martin L; Dixon GH; Fritzler MJ
    J Rheumatol; 1994 Nov; 21(11):2071-5. PubMed ID: 7869312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dysimmune rheumatism in Raynaud's syndrome (inflammatory rheumatism, Raynaud's syndrome, speckled antinuclear factors and anti-ribonucleoprotein antibody): a new syndrome?].
    Appelboom T; Kahn MF; Peltier AP; de SEZE S
    Ann Med Interne (Paris); 1974 Nov; 125(11):841-8. PubMed ID: 4218716
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon.
    Riente L; Marchini B; Dolcher MP; Puccetti A; Bombardieri S; Migliorini P
    Clin Exp Immunol; 1995 Nov; 102(2):354-9. PubMed ID: 7586690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerodermic lesions after liposuction in a patient with Raynaud's phenomenon and anti-centromeric antibodies.
    Galeazzi M; De Pità O; Porciello G; Bellisai F
    Clin Exp Rheumatol; 2001; 19(4):484. PubMed ID: 11491519
    [No Abstract]   [Full Text] [Related]  

  • 9. [Relations between Raynaud's disease and scleroderma in the framework of immunological research].
    FARINELLI A; RIPA R; GRANDI L
    Arcisp S Anna Ferrara; 1960; 13(Suppl 6)():1491-517. PubMed ID: 13698198
    [No Abstract]   [Full Text] [Related]  

  • 10. [Raynaud's phenomenon and systemic diseases: immunological viewpoint].
    Lantin JP; Duc J
    Rev Med Suisse Romande; 1992 May; 112(5):401-4. PubMed ID: 1604100
    [No Abstract]   [Full Text] [Related]  

  • 11. Human anticentriole autoantibody in patients with scleroderma and Raynaud's phenomenon.
    Moroi Y; Murata I; Takeuchi A; Kamatani N; Tanimoto K; Yokohari R
    Clin Immunol Immunopathol; 1983 Dec; 29(3):381-90. PubMed ID: 6357574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Esophageal motor changes in patients with Raynaud's phenomenon and suspected scleroderma. Electromanometric and serologic evaluations].
    Benevento A; Barcellini W; Maestri L; Riva R; Sabbadini MG; Veralli E
    Minerva Med; 1984 Sep; 75(37):2111-8. PubMed ID: 6483266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antibodies to collagen type I and fibronectin in patients with scleroderma systemic ].
    Taova MK; Kurdanov KA
    Klin Med (Mosk); 1996; 74(7):50-1. PubMed ID: 8992117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
    Seishima M; Izumi T; Kanoh H
    Eur J Dermatol; 2000; 10(1):55-8. PubMed ID: 10694301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticentromere and anticentriole antibodies in the scleroderma spectrum.
    Tuffanelli DL; McKeon F; Kleinsmith DM; Burnham TK; Kirschner M
    Arch Dermatol; 1983 Jul; 119(7):560-6. PubMed ID: 6859899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
    Vázquez-Abad D; Grodzicky T; Senécal JL
    Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies and clinical subsets: relevance to scleroderma.
    Maddison PJ
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):684-6. PubMed ID: 11020957
    [No Abstract]   [Full Text] [Related]  

  • 19. Infrequency of anticentromere antibody in patients without systemic sclerosis and without Raynaud's phenomenon.
    Migliaresi S; Picillo U; Terri G; Improta RD; La Palombara F; Giordano M
    Arthritis Rheum; 1987 Mar; 30(3):358-9. PubMed ID: 3494456
    [No Abstract]   [Full Text] [Related]  

  • 20. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma.
    Tubach F; Hayem G; Elias A; Nicaise P; Haim T; Kahn MF; Meyer O
    Rev Rhum Engl Ed; 1997 Jun; 64(6):362-7. PubMed ID: 9513607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.